Embryo–fetal toxicity signals for 17α-hydroxyprogesterone caproate in high-risk pregnancies: A review of the non-clinical literature for embryo–fetal toxicity with progestins

References

• Meis P J, Klebanoff M, Thorn E, Dombrowski M P, Sibai B, Moawad A H, Spong C Y, Hauth J C, Miodovnik M, Varner M W, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. New Engl J Med 2003; 348: 2379–2385
   PubMed Web of Science ®Google Scholar
• da Fonseca E B, Bittar R E, Carvalho M H, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419–424
   PubMed Web of Science ®Google Scholar
• Wiseman R A, Dodds-Smith I C. Cardiovascular birth defects and antenatal exposure to female sex hormones: A reevaluation of some base data. Teratology 1984; 30: 359–370
   PubMedGoogle Scholar
• Heinonen O P, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Publishing Science Group, Inc., Littleton, Massachusetts 1977
   Google Scholar
• Loose-Mitchell D S, Stancel G M. Estrogens and progestins. Goodman & Gilman's The pharmacological basis of therapeutics10th Ed., J G Hardman, L E Linbird. McGraw-Hill, New York 2001; 1597–1634
   Google Scholar
• Sexton D J, O'Reilly W O, Friel A M, Morrison J J. Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro. Reprod Biol Endocrinol 2004; 2: 80–86
   PubMedGoogle Scholar
• Schardein J L. Chemically induced birth defects. Marcel Dekker, New York 1985; 275–299
   Google Scholar
• Shepard T H. Catalog of teratogenic agents6th Ed. John Hopkins University Press, Baltimore 1989; 526–527
   Google Scholar
• Wikipedia, Available at: http://en.wikipedia.org/wiki/Progesterone (accessed September 2006)
   Google Scholar
• DiRenzo G C, Matei A, Gojnic M, Gerli S. Progesterone and pregnancy. Curr Opin Obstet Gynecol 2005a; 17: 598–600
   PubMedGoogle Scholar
• DiRenzo G C, Rosati A, Mattei A, Gojnic M, Gerli S. The changing role of progesterone in preterm labour. Br J Obstet Gynaecol 2005; 112(Suppl 1)57–60
   Google Scholar
• Wikipedia, Available at: http://en.wikipedia.org/wiki/17-hydroxyprogesterone (accessed September 2006)
   Google Scholar
• Goldstein P, Berrier J, Rosen S, Sacks H S, Chalmers T C. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989; 96: 265–274
   PubMedGoogle Scholar
• Keirse M J. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990; 97: 149–154
   PubMedGoogle Scholar
• Oates-Whitehead R M, Haas D M, Carrier J A. Progestogen for preventing miscarriage (Review). Cochrane Database Syst Rev 2003; 4, CD003511
   Google Scholar
• Yemini M, Borenstein E, Dreazen S, Apelman Z, Mogilner B M, Kessler I, Lancet M. Prevention of premature labor by 17α-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985; 151: 574–577
   PubMed Web of Science ®Google Scholar
• Schardein J L. Congenital abnormalities and hormones during pregnancy: A clinical review. Teratology 1980; 22: 251–270
   PubMedGoogle Scholar
• Wilkins L. Masculinization of female fetus due to use of orally given progestins. JAMA 1960; 172: 1028–1032
   PubMed Web of Science ®Google Scholar
• Venning G R. The problem of human foetal abnormalities with special reference to sex hormones. Embryopathic activity of drugs, J M Robson, F M Sullivan, R L Smith. Churchill, London 1965; 94–104
   Google Scholar
• Cahen R L. Experimental and clinical chemoteratogenesis. Adv Pharmacol 1966; 4: 263–349
   Google Scholar
• Leibow S G, Gardner L I. Genital abnormalities in infants associated with administration of progesteroids to their mother. Pediatrics 1960; 26: 151–160
   PubMedGoogle Scholar
• Cope E, Emelife E C. Habitual abortion treated with 17α-hydroxyprogesterone caproate. J Obstet Gynaecol Br Commonw 1965; 72: 1035–1037
   Google Scholar
• Serment H, Ruf H. Les dangers pour le produit de conception de medicaments administers a la femme enceinte. Bull Fed Soc Gynecol Obstet Lang Fr 1968; 20: 69–76
   Google Scholar
• Wilson J G, Brent R L. Are female sex hormones teratogenic?. Am J Obstet Gynecol 1981; 141: 567–580
   PubMedGoogle Scholar
• US Food and Drug Administration (US FDS, 1977). Labeling of progestational agents. July 22, 1977; 42: 37643–37648, Federal Register No. 141 (1977)
   Google Scholar
• US Food and Drug Administration (US FDA, 1979a). FDA Drug Bulletin. Patient brochure for progestins warns against use in pregnancy. December 1978–January, 1979; 8: 36–37
   Google Scholar
• Corfman P A. Labeling guidance text for combination oral contraceptives: Physician labeling review, February 11, 1988. Contraception 1988; 37: 433–455
   Google Scholar
• US Food and Drug Administration (US FDA, 1999). Progestational drug products for human use; requirements for labeling directed to the patient. Federal Register. 64, No. 70. Proposed rules, Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA), 21 CFR Part 310, (Docket No. 99N–0188), 64 FR 17985
   Google Scholar
• Brent R L. Nongenital malformations following exposure to progestational drugs: The last chapter of an erroneous allegation. Birth Defects Res (Part A) 2005; 73: 906–918
   PubMedGoogle Scholar
• US Food and Drug Administration (US FDA, 1994). International Conference on Harmonisation. Guideline on detection of toxicity to reproduction for medicinal products. September 22, 1994; 59, Federal Register. No. 183
   Google Scholar
• Christian M S. Test methods for assessing female reproductive and developmental toxicology. Principles and methods of toxicology4th Ed., A W Hayes. Taylor & Francis, Philadelphia 2001; 1301–1381
   Google Scholar
• Christian M S, Hoberman A M, Lewis E M. Perspectives on the developmental toxicity guidelines. Handbook of developmental toxicology, R D Hood. Taylor & Francis, Philadelphia 2005; 733–798
   Google Scholar
• US Food and Drug Administration (US FDA, 1978 et seq.). Good laboratory practice regulations, Final Rule. 21 CFR Part 58
   Google Scholar
• California E PA. Reproductive and Cancer Hazard Assessment Section, Office of Environmental Health Hazard Assessment. 2004. Evidence on the developmental and reproductive toxicity of progesterone. August 2004; 13–14
   Google Scholar
• IARC Monographs on the evaluation of carcinogenic risk of chemicals to man. Lyon 1979; 21: 399–406
   Google Scholar
• IARC Summaries and Evaluation. Progestins (group B). 1987, Supplement 7, Available at: http://www.inchem.org/documents/iarc/suppl7/progestins.html (accessed January 2006)
   Google Scholar
• Umancheeva A F, Novikova A I, Anisomov V N. [Stimulating effect of pregnancy on growth on cervical cancer] (article in Russian). Akush Ginekol 1981; 1: 53–55
   Google Scholar
• US Food and Drug Administration (US FDA, 1979b). Federal Food, Drug, and Cosmetic Act, 21 CFR 201.57(f)(6)
   Google Scholar
• US Food and Drug Administration (US FDA, 1997). Content and format of labeling for human prescription drugs. Food and Drug Administration Center for Drug Evaluation and Research, BethesdaMD, USA September 12, 1997, Part 15, Public hearing – pregnancy labeling categories
   Google Scholar
• US Food and Drug Administration (US FDA, 2001). Draft reviewer guidance. Integration of study results to assess concerns about human reproductive and developmental toxicities, Available at: http://www.fda.gov/cder/guidance/index.htm (accessed January 2007)
   Google Scholar
• Fortune J E, Vincent S E. Progesterone inhibits the induction of aromatase activity in rat granulosa cells in vitro. Biol Reprod 1983; 28: 1078–1089
   PubMedGoogle Scholar
• Smithberg M, Runner M N. The induction and maintenance of pregnancy in prepubertal mice. J Exptl Zool 1956; 133: 441–457
   Google Scholar
• Abdul-Karim R W, Nesbitt R E, Drucker M H, Rizk P T. The regulatory effect of estrogens on fetal growth. I. Placental and fetal body weights. Am J Obstet Gynecol 1971; 109: 656–661
   PubMedGoogle Scholar
• Wu D H. Maintenance of pregnancy in castrated rabbits by an orally active progestational agent: 6α-methyl 17α-hydroxyprogesterone acetate. Fertil Steril 1961; 12: 236–244
   PubMedGoogle Scholar
• Wu D H, Allen W M. Maintenance of pregnancy in castrated rabbits by 17-alpha-hydroxy-progesterone and by progesterone. Fertil Steril 1959; 10: 439
   PubMedGoogle Scholar
• Wharton L R, Scott R B. Experimental production of genital lesions with norethindrone. Am J Obstet Gynecol 1964; 89: 701–715
   PubMedGoogle Scholar
• Bührdel P, Willgerodt H, Theile H. [Gestation time prolonging effect of progesterone and various synthetic gestagens in the rat] (article in German). Acta Biol Med Ger 1974; 32: 193–198
   PubMedGoogle Scholar
• Saunders F J. The effects of several steroids on fecundity in female rats. Endocrinology 1958; 63: 561–565
   PubMedGoogle Scholar
• Peterson D L, Edgren R A. The effect of various steroids on mating behavior, fertility and fecundity of rats. Int J Fertil 1965; 10: 327–332
   PubMedGoogle Scholar
• Gabriel-Robez O, Rohmer A, Clavert J, Schneegans E. [Teratogenic and lethal actions of diethylstilbestrol on the mouse embryo] (article in French). Arch Fr Pediatr 1972; 29: 149–154
   PubMedGoogle Scholar
• Khera K S. Common fetal aberrations and their teratologic significance: A review. Fund Appl Toxicol 1981; 1: 13–18
   PubMedGoogle Scholar
• Khera K S. Maternal toxicity: A possible factor in fetal malformations in mice. Teratology 1985; 29: 411–416
   Google Scholar
• Bartholomeusz R K, Bruce N W. Effects of maternal progesterone supplementation on fetal, placental and corpus luteal weights in the rat. Biol Reprod 1976; 15: 84–89
   PubMedGoogle Scholar
• Alloiteau J J, Acker G. [The control of placental weight he ovarian hormones in rats] (article in French). C R Hebd Seances Acad Sci 1962; 254: 3901–3903
   PubMedGoogle Scholar
• Foote W D, Foote W C. Influence of certain natural and synthetic steroids on genital development in guinea pigs. Fertil Steril 1968; 19: 606–615
   PubMed Web of Science ®Google Scholar
• Kimmel C A, Wilson J G. Skeletal deviations in rats – malformations or variations. Teratology 1973; 8: 309–315
   PubMedGoogle Scholar
• Green R M, Kochar D M. Some aspects of cortisone-induced cleft-palate – review. Teratology 1975; 11: 47–55
   PubMedGoogle Scholar
• Pepe G J, Rothchild I. Metabolic clearance rate of progesterone: Comparison between ovariectomized, pregnant, pseudopregnant and deciduoma-bearing pseudopregnant rats. Endocrinology 1973; 93: 1200–1205
   PubMedGoogle Scholar
• Coyle I R, Anker R, Cragg B. Behavioral, biochemical and histological effects of prenatal administration of progesterone in the rat. Pharmacol Biochem Behav 1976; 5: 587–590
   PubMed Web of Science ®Google Scholar
• Smithberg M. Attempts to induce and maintain pregnancy in prepuberal mice following treatment with 17α-hydroxyprogesterone 17-n-caproate. Ann N Y Acad Sci 1958; 71: 555–559
   PubMedGoogle Scholar
• Lopez J, Ogren L, Verjan R, Talamantes F. Effects of perinatal exposure to a synthetic estrogen and progestin on mammary tumorigenesis in mice. Teratology 1988; 38: 129–134
   PubMedGoogle Scholar
• Suchowsky G K, Junkmann K. A study of the virilizing effect of progestogens on the female rat fetus. Endocrinology 1961; 68: 341–349
   Google Scholar
• McKinnon A O, Figueroa T D, Nobelius A M, Hyland J H, Vasey J R. Failure of hydroxyprogesterone caproate to maintain pregnancy in ovariectomised mares. Equine Vet J 1993; 25: 158–160
   PubMedGoogle Scholar
• NIOSH. The registry of toxic effects of chemical substances. 2003, Pregn-4-ene-3,20-dione, 17-hydroxy-hexanoate; Available at: http://www.cdc.gov/niosh/rtecs/tu4d9748.html (accessed January 2006)
   Google Scholar
• Seegmiller R E, Nelson G W, Johnson C K. Evaluation of teratogenic potential of delalutin (17α-hydroxyprogesterone caproate) in mice. Teratology 1983; 28: 201–208
   PubMedGoogle Scholar
• Hendrickx A G, Korte R, Leuschner F, Neumann B W, Poggel A, Binkerd P, Prahalada S, Günzel P. Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate. Teratology 1987; 35: 129–136
   PubMedGoogle Scholar
• Clark R L, Anderson C A, Prahalada S, Robertson R T, Lochry E A, Leonard Y M, Stevens J L, Hoberman A M. Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5α-reductase inhibitor. Toxicol Appl Pharmacol 1993; 119: 34–40
   PubMedGoogle Scholar
• Jung H, Peters A. [The action of various gestagens upon the development of the foetus and the incidence of deaths in animal experiments] (article in German). Arch Gynaekol 1967; 204: 68–77
   PubMedGoogle Scholar
• Courtney K D, Valerio D A. Teratology in the Macaca mulatta. Teratology 1968; 1: 163–172
   PubMedGoogle Scholar
• Junkmann K. Über protrahiert wirksame Gestagene. [Prolonged-acting progestogens] (article in German). Arch Exper Path Pharmakol 1954; 223: 244–253
   PubMedGoogle Scholar
• Kessler W, Borman A. Some biological activities of certain progestogens. Ann NY Acad Sci 1958; 71: 486–493
   PubMedGoogle Scholar
• Johnstone E E, Franklin R R. Assay of progestins for fetal virilizing properties using the mouse. Obstet Gynecol 1964; 23: 359–362
   PubMed Web of Science ®Google Scholar
• Carbone J P, Buck S J, Figurska K, Brent R L. The effects of intra-uterine medroxyprogesterone acetate (MPA), 17-hydroxyprogesterone caproate (17-OH PC), norethindrone (N), or triamcinolone acetonide (TA) exposure on embryonic development. Teratology 1987; 35: 28A, (abstract 11)
   Google Scholar
• Carbone J P, Brent R L. Genital and nongenital teratogenesis of prenatal progestogen therapy: The effects of 17α-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse. Am J Obstet Gynecol 1993; 169: 1292–1298
   PubMedGoogle Scholar
• Janerich D T, Piper J M, Glebatis D M. Oral contraceptives and congenital limb reduction defects. N Engl J Med 1974; 291: 697–700
   PubMed Web of Science ®Google Scholar
• Pickworth S, Lamming G E. Observations on pregnancy in intact rabbits and in ovariectomized rabbits treated with 17 alpha-hydroxyprogesterone caproate. J Reprod Fertil 1967; 13: 457–468
   PubMedGoogle Scholar
• Padmanabhan R, Hameed M S. Effect of progesterone during late gestation on the gestation length, postnatal survival and growth of offspring in the rat. Teratology 1985; 31: 48A, (abstract P26)
   Google Scholar
• Pushpalatha T, Reddy P R, Reddy P S. Effect of prenatal exposure to hydroxyprogesterone on steroidogenic enzymes in male rats. Naturwissenschaften 2003; 90: 40–43
   PubMedGoogle Scholar
• Pushpalatha T, Reddy P R, Reddy P S. Impairment of male reproduction in adult rats exposed to hydroxyprogesterone caproate in utero. Naturwissenschaften 2004; 91: 242–244
   PubMedGoogle Scholar
• Lopez J, Ogren L, Talamantes F. Effects of neonatal treatment with diethylstilbestrol and 17-α-hydroxyprogesterone caproate on in vitro pituitary prolactin secretion. Life Sci 1984; 34: 2303–2311
   PubMedGoogle Scholar
• Garry D, Figueroa R, Guillaume J, Cucco V. Use of castor oil in pregnancies at term. Altern Ther Health Med 2000; 6: 77–79
   PubMed Web of Science ®Google Scholar
• Hirzel S. Caproic acid. 2002, BUA Report 241
   Google Scholar